Institution
National Jewish Health
Healthcare•Denver, Colorado, United States•
About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: T cell & Asthma. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.
Topics: T cell, Asthma, Population, Lung, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The long distance interaction between the sites of allergic inflammation and the site of hematopoiesis in the bone marrow is reviewed, the characteristics of innate type-2 progenitors are studied, and the molecular mechanisms by which innatetype-2 effector cells acquire the capacity to produce type- 2 cytokines are focused on.
Abstract: Type-2 immune responses are the underlying cause of many allergic diseases and provide protection against parasitic infection. Effective type-2 immune responses are generated by type-2 helper CD4+ T cells (Th2) as well as type-2 innate effector cells. While we have learned a great deal about how CD4+ Th2 cells regulate their Th2 cytokine gene transcription, we still do not know how type-2 innate effector cells acquire their capacity to express Th2 cytokine genes. Furthermore, it remains poorly understood how Th2 cytokines regulate the differentiation of innate type-2 progenitor cells. In this review, we will focus on (1) the long distance interaction between the sites of allergic inflammation and the site of hematopoiesis in the bone marrow, (2) the characteristics of innate type-2 progenitors, and (3) the molecular mechanisms by which innate type-2 effector cells acquire the capacity to produce type-2 cytokines.
3 citations
••
TL;DR: It is shown that incorporating functional annotations can better prioritize GWAS signals at both the global and the local levels, and suggest that rich signals for COPD genetics are still buried under the Bonferroni-corrected genome-wide significance threshold.
Abstract: Rich collections of genomic and epigenomic annotations, availabilities of large population cohorts for genome-wide association studies (GWAS), and advancements in data integration techniques provide the unprecedented opportunity to accelerate discoveries in complex disease studies through integrative analyses. In this paper, we apply a variety of approaches to integrate GWAS summary statistics of chronic obstructive pulmonary disease (COPD) with functional annotations to illustrate how data integration could help researchers understand complex human diseases. We show that incorporating functional annotations can better prioritize GWAS signals at both the global and the local levels. Signal prioritization on severe COPD GWAS reveals multiple potential risk loci that are linked with pulmonary functions. Enrichment analysis provides novel insights on the pathogenesis of COPD and hints the existence of genetic contributions to muscle dysfuncion and chronic lung inflammation, two symptoms that are often co-morbid with COPD. Our results suggest that rich signals for COPD genetics are still buried under the Bonferroni-corrected genome-wide significance threshold. Many more biological findings are expected to emerge as more samples are recruited for COPD studies.
3 citations
••
01 Jan 20053 citations
•
3 citations
••
01 Jan 2010TL;DR: Patients were more adherent to oral than inhaled medications among 17 studies meeting inclusion criteria for this review, and indirect evidence indicates that patient’s preference for oral medication is not related to dosing frequency.
Abstract: In this chapter, we provide a systematic review of randomized controlled trials, meta-analysis, case-control, or cohort studies that compared patient adherence with, or preference for, oral or inhaled controller medication for asthma. Among 17 studies meeting inclusion criteria for our review, patients were more adherent to oral than inhaled medications. Where queried, patients or parents expressed preference for oral medications. These findings were consistent across study designs, using contrasting measures of adherence, over varied time periods and including many with 12-month follow-up, and with patients who knew they were being monitored as well as those included in an anonymous database. Indirect evidence indicates that patient’s preference for oral medication is not related to dosing frequency.
3 citations
Authors
Showing all 901 results
Name | H-index | Papers | Citations |
---|---|---|---|
Thomas V. Colby | 126 | 501 | 60130 |
John W. Kappler | 122 | 464 | 57541 |
Donald Y.M. Leung | 121 | 614 | 50873 |
Philippa Marrack | 120 | 416 | 54345 |
Jeffrey M. Drazen | 117 | 693 | 52493 |
Peter M. Henson | 112 | 369 | 54246 |
David A. Schwartz | 110 | 958 | 53533 |
David A. Lynch | 108 | 714 | 59678 |
Norman R. Pace | 101 | 297 | 50252 |
Kevin K. Brown | 100 | 387 | 47219 |
Stanley J. Szefler | 99 | 554 | 37481 |
Erwin W. Gelfand | 99 | 675 | 36059 |
James D. Crapo | 98 | 473 | 37510 |
Yang Xin Fu | 97 | 390 | 33526 |
Stephen D. Miller | 94 | 433 | 30499 |